Is survodutide the same as mazdutide?
No. They are different experimental drugs that happen to hit the same two receptors, GLP-1 and glucagon. Survodutide's profile holds a 387-person obesity study (down 14.9% versus down 2.8%) and liver-disease studies in 293 and 216 adults. It is not approved anywhere this site tracks. Mazdutide's profile holds a 731-person head to head study against dulaglutide and GLORY-1 in 610 adults, and it is approved in China, not by the FDA. Sharing two receptors does not make them the same molecule, the same study, or the same approval. This site does not rank them. Full records at /compounds/survodutide and /compounds/mazdutide.
Studies in people from the compound pages this answer belongs to
- Mazdutide
- Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1) 2025 PMID 40421736
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes 2026 PMID 41407860
- Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial 2026 PMID 42251595
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.
Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.